PMID- 35527666
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220510
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 50
IP  - 3
DP  - 2022
TI  - The comparative effect of Leukotriene receptor antagonist add on therapy and step 
      up inhaled Corticosteroid in partially controlled asthma: An open-labeled 
      randomized controlled trial.
PG  - 125-131
LID - 10.15586/aei.v50i3.553 [doi]
AB  - BACKGROUND: No studies are comparing the impact of the add-on 
      leukotriene-receptor antagonist (LTRA) with a step-up dose of inhaled 
      corticosteroids (ICS) in partly controlled asthma patients with asthma control 
      test (ACT) score < 23. OBJECTIVE: To study the effect of LTRA add-on therapy in 
      comparison to a step-up to medium dose of ICS in partially controlled asthma. 
      METHODS: An open-labeled randomized controlled trial was conducted in asthma 
      subjects with partly controlled asthma who had been in regular receipt of low 
      dose ICS. All subjects were assessed for asthma using ACT, daytime and nighttime 
      symptoms, rate of relievers used, spirometry, and impulse oscillometry (IOS) at 3 
      and 6 months. Subjects were randomized to receive daily oral LTRA 10 mg or 
      step-up medium dose of ICS. RESULTS: Between June 2020 and January 2021, 50 
      participants were enrolled, all patients completing the study. After treatment, 
      mean ACT scores were increased to more than 23 indicating well-controlled asthma 
      in both groups, control being sustained throughout the whole 6-month study period 
      (P < 0.001). Within each group, ACT scores were improved by a minimal clinical 
      important difference (MCID) >/= 3 points at 6 months, compared to baseline values. 
      There were significant decreases in nighttime and daytime symptoms, and the 
      numbers of rescue relievers used in 4 weeks in both groups compared to baseline 
      (P < 0.001). CONCLUSIONS: LTRA add-on therapy in partially controlled asthma 
      patients is comparable with step-up to medium dose of ICS/LABA as regards asthma 
      control.
FAU - Ruenwilai, Parinya
AU  - Ruenwilai P
AD  - Division of Pulmonary, Critical Care and Allergy, Department of Internal 
      Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
FAU - Theerakittikul, Theerakorn
AU  - Theerakittikul T
AD  - Division of Pulmonary, Critical Care and Allergy, Department of Internal 
      Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 
      theerakorn.t@cmu.ac.th.
FAU - Chaiwong, Warawut
AU  - Chaiwong W
AD  - Division of Pulmonary, Critical Care and Allergy, Department of Internal 
      Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
FAU - Phetsuk, Nittaya
AU  - Phetsuk N
AD  - Division of Pulmonary, Critical Care and Allergy, Department of Internal 
      Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
FAU - Pothirat, Chaicharn
AU  - Pothirat C
AD  - Division of Pulmonary, Critical Care and Allergy, Department of Internal 
      Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
FAU - Liwsrisakun, Chalerm
AU  - Liwsrisakun C
AD  - Division of Pulmonary, Critical Care and Allergy, Department of Internal 
      Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220501
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Leukotrienes)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - *Anti-Asthmatic Agents/therapeutic use
MH  - *Asthma/drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Leukotriene Antagonists/therapeutic use
MH  - Leukotrienes/therapeutic use
OTO - NOTNLM
OT  - Asthma
OT  - asthma control
OT  - inhaled corticosteroids
OT  - leukotriene-receptor antagonists
OT  - lung function
COIS- The authors declare that there is no conflict of interest in this work.
EDAT- 2022/05/10 06:00
MHDA- 2022/05/11 06:00
CRDT- 2022/05/09 03:16
PHST- 2021/12/01 00:00 [received]
PHST- 2022/02/16 00:00 [accepted]
PHST- 2022/05/09 03:16 [entrez]
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
AID - 10.15586/aei.v50i3.553 [doi]
PST - epublish
SO  - Allergol Immunopathol (Madr). 2022 May 1;50(3):125-131. doi: 
      10.15586/aei.v50i3.553. eCollection 2022.